Many bone remodeling models explore the effects of one or more drugs on bone health (Supplementary Material Tables ). Researchers typically start by modeling a healthy or diseased remodeling cycle (or leveraging existing models) and then extend the process to include drug effects. For example, glucocorticoid therapies and their interactions with the bone remodeling cycle are modeled in . These models alter one parameter related to a symptom of glucocorticoid treatment, specifically reduced osteoblast populations. This essentially involves reducing α OBL in Equation (10) or Equation (11). However, reducing one parameter corresponding to an effect observed with glucocorticoid